Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

NCT ID: NCT00566852

Last Updated: 2017-08-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

554 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.

PURPOSE: This randomized phase III trial is studying memantine to see how well it works compared to a placebo in preventing side effects caused by whole-brain radiation therapy in patients with brain metastases from solid tumors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Determine whether the addition of memantine hydrochloride to whole-brain radiotherapy (WBRT) preserves cognitive function, specifically memory, as measured by the Hopkins Verbal Learning Test for delayed recall (HVLT-delayed recall), over that of placebo and WBRT in patients with brain metastases at 24 weeks from the start of drug treatment.

Secondary

* Determine whether the addition of memantine hydrochloride preserves cognitive function, specifically memory, as measured by the HVLT-delayed recall at 8 weeks, 16 weeks, and 12 months from the start of drug treatment.
* Determine whether the addition of memantine hydrochloride increases time to neurocognitive failure as measured by cognitive decline on a battery of tests including the HVLT for free recall, delayed recall, and delayed recognition; the Controlled Word Association Test (COWAT); the Trail Making Test Parts A and B (TMT); the Medical Outcomes Scale-Cognitive Functioning Subscale (MOS); and the Mini-Mental Status Examination (MMSE).
* Evaluate the potential benefit of memantine hydrochloride in change and overall quality of life, as measured by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) subscale.
* Determine whether the addition of memantine hydrochloride increases progression-free survival.
* Determine whether the addition of memantine hydrochloride increases overall survival.
* Compare adverse events between the treatment arms according to the CTCAE v3.0 criteria.
* Collect serum, plasma, buffy coat cells, urine, and cerebrospinal fluid (CSF) for future translational research analyses.

OUTLINE: This is a multicenter study. Patients are stratified according to recursive partitioning analysis (RPA) prognostic class (class I vs class II with controlled systemic disease) and prior surgical therapy (none vs radiosurgery or surgical resection). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo whole-brain radiotherapy (WBRT) 5 days a week for 3 weeks (15 fractions). Patients also receive oral memantine hydrochloride once daily beginning on day 1 of WBRT and continuing for 24 weeks.
* Arm II: Patients undergo WBRT as in arm I. Patients also receive oral placebo once daily beginning on day 1 of WBRT and continuing for 24 weeks.

After completion of study treatment, patients are followed at 6 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive/Functional Effects Metastatic Cancer Neurotoxicity Unspecified Adult Solid Tumor, Protocol Specific

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

WBRT+Memantine

Whole brain radiation therapy (WBRT) and memantine

Group Type EXPERIMENTAL

Memantine

Intervention Type DRUG

Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.

Whole brain radiation therapy

Intervention Type RADIATION

Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy

WBRT+Placebo

Whole brain radiation therapy (WBRT) and placebo

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type OTHER

Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.

Whole brain radiation therapy

Intervention Type RADIATION

Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Memantine

Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.

Intervention Type DRUG

Placebo

Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.

Intervention Type OTHER

Whole brain radiation therapy

Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who had undergone radiosurgery or surgical resection and are planning adjuvant whole-brain radiotherapy do not have to have visible disease but do need a baseline MRI
* Must have stable systemic disease (i.e. no evidence of systemic disease progression within the past 3 months)
* Patients with brain metastases at initial presentation are eligible and do not need to demonstrate 3 months of stable scans

PATIENT CHARACTERISTICS:

Inclusion

* Karnofsky performance status 70-100%
* Serum creatinine ≤ 3 mg/dL and creatinine clearance ≥ 30 mL/min
* Total bilirubin ≤ 2.5 mg/dL
* Blood urea nitrogen (BUN) \< 20 mg/dL
* Mini-mental status exam score ≥ 18
* Negative serum pregnancy test
* Fertile patients must practice adequate contraception

Exclusion

* Severe, active co-morbidity, defined as follows:

* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
* Transmural myocardial infarction within the last 6 months
* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
* Pregnant or lactating women
* Prior allergic reaction to memantine hydrochloride
* Current alcohol or drug abuse
* Intractable seizures while on adequate anticonvulsant therapy (i.e., more than one seizure per month for the past 2 months)

PRIOR CONCURRENT THERAPY:

Inclusion

* At least 14 days but no more than 56 days since prior therapy for brain metastasis, including radiosurgery and surgical resection
* No systemic chemotherapy for 14 days prior, during, or for 14 days after completion of whole-brain radiotherapy (WBRT)

Exclusion

* Prior cranial radiotherapy

* Patients may have received up to 3 prior WBRT treatments and still be registered and randomized on the protocol provided WBRT parameters meet protocol requirements
* Chronic short-acting benzodiazepine use
Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

NRG Oncology

OTHER

Sponsor Role collaborator

Radiation Therapy Oncology Group

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul D. Brown, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Christina A. Meyers, PhD

Role: STUDY_CHAIR

M.D. Anderson Cancer Center

Sherry Fox, RN, PhD

Role: STUDY_CHAIR

Bon Secours Cancer Institute at St. Mary's Hospital

Deepak Khuntia, MD

Role: STUDY_CHAIR

University of Wisconsin, Madison

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MBCCOP - Gulf Coast

Mobile, Alabama, United States

Site Status

Providence Cancer Center at Providence Hospital

Mobile, Alabama, United States

Site Status

Arizona Oncology Services Foundation

Phoenix, Arizona, United States

Site Status

Mayo Clinic Scottsdale

Scottsdale, Arizona, United States

Site Status

Arizona Oncology - Tucson

Tucson, Arizona, United States

Site Status

Arizona Cancer Center at University of Arizona Health Sciences Center

Tucson, Arizona, United States

Site Status

Auburn Radiation Oncology

Auburn, California, United States

Site Status

Providence Saint Joseph Medical Center - Burbank

Burbank, California, United States

Site Status

Radiation Oncology Centers - Cameron Park

Cameron Park, California, United States

Site Status

Mercy Cancer Center at Mercy San Juan Medical Center

Carmichael, California, United States

Site Status

Enloe Cancer Center at Enloe Medical Center

Chico, California, United States

Site Status

Cancer Care Center at John Muir Health - Concord Campus

Concord, California, United States

Site Status

City of Hope Comprehensive Cancer Center

Duarte, California, United States

Site Status

Glendale Adventist Medical Center

Glendale, California, United States

Site Status

Rebecca and John Moores UCSD Cancer Center

La Jolla, California, United States

Site Status

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

USC/Norris Comprehensive Cancer Center and Hospital

Los Angeles, California, United States

Site Status

St. Joseph Hospital Regional Cancer Center - Orange

Orange, California, United States

Site Status

Radiation Oncology Center - Roseville

Roseville, California, United States

Site Status

Radiological Associates of Sacramento Medical Group, Incorporated

Sacramento, California, United States

Site Status

University of California Davis Cancer Center

Sacramento, California, United States

Site Status

Mercy General Hospital

Sacramento, California, United States

Site Status

Stanford Cancer Center

Stanford, California, United States

Site Status

Emanuel Regional Cancer Services at Emanuel Medical Center

Turlock, California, United States

Site Status

Solano Radiation Oncology Center

Vacaville, California, United States

Site Status

John Muir/Mt. Diablo Comprehensive Cancer Center

Walnut Creek, California, United States

Site Status

Rocky Mountain Cancer Centers - Aurora

Aurora, Colorado, United States

Site Status

Rocky Mountain Cancer Centers - Colorado Springs

Colorado Springs, Colorado, United States

Site Status

Poudre Valley Radiation Oncology

Fort Collins, Colorado, United States

Site Status

Yale Cancer Center

New Haven, Connecticut, United States

Site Status

CCOP - Christiana Care Health Services

Newark, Delaware, United States

Site Status

Washington Cancer Institute at Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

University of Florida Shands Cancer Center

Gainesville, Florida, United States

Site Status

Baptist Cancer Institute - Jacksonville

Jacksonville, Florida, United States

Site Status

Integrated Community Oncology Network at Southside Cancer Center

Jacksonville, Florida, United States

Site Status

Baptist Medical Center South

Jacksonville, Florida, United States

Site Status

Integrated Community Oncology Network

Jacksonville Beach, Florida, United States

Site Status

Integrated Community Oncology Network - Orange Park

Orange Park, Florida, United States

Site Status

Florida Institute of Research, Medicine and Surgery Cancer Center

Orlando, Florida, United States

Site Status

Florida Cancer Center - Palatka

Palatka, Florida, United States

Site Status

Flagler Cancer Center

Saint Augustine, Florida, United States

Site Status

Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

Site Status

John B. Amos Cancer Center

Columbus, Georgia, United States

Site Status

Veterans Affairs Medical Center - Atlanta (Decatur)

Decatur, Georgia, United States

Site Status

Northeast Georgia Medical Center

Gainesville, Georgia, United States

Site Status

Northwest Community Hospital

Arlington Heights, Illinois, United States

Site Status

John H. Stroger, Jr. Hospital of Cook County

Chicago, Illinois, United States

Site Status

Cancer Institute at St. John's Hospital

Springfield, Illinois, United States

Site Status

CCOP - Carle Cancer Center

Urbana, Illinois, United States

Site Status

Saint John's Cancer Center at Saint John's Medical Center

Anderson, Indiana, United States

Site Status

Bloomington Hospital Regional Cancer Institute

Bloomington, Indiana, United States

Site Status

Radiation Oncology Associates Southwest

Fort Wayne, Indiana, United States

Site Status

Parkview Regional Cancer Center at Parkview Health

Fort Wayne, Indiana, United States

Site Status

Center for Cancer Care at Goshen General Hospital

Goshen, Indiana, United States

Site Status

Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, United States

Site Status

Methodist Cancer Center at Methodist Hospital

Indianapolis, Indiana, United States

Site Status

Central Indiana Cancer Centers - East

Indianapolis, Indiana, United States

Site Status

Community Regional Cancer Care at Community Hospital East

Indianapolis, Indiana, United States

Site Status

Community Regional Cancer Care at Community Hospital North

Indianapolis, Indiana, United States

Site Status

Cancer Center at Ball Memorial Hospital

Muncie, Indiana, United States

Site Status

CCOP - Northern Indiana CR Consortium

South Bend, Indiana, United States

Site Status

Holden Comprehensive Cancer Center at University of Iowa

Iowa City, Iowa, United States

Site Status

Kansas City Cancer Centers - Southwest

Overland Park, Kansas, United States

Site Status

Lucille P. Markey Cancer Center at University of Kentucky

Lexington, Kentucky, United States

Site Status

Norton Suburban Hospital

Louisville, Kentucky, United States

Site Status

Greenebaum Cancer Center at University of Maryland Medical Center

Baltimore, Maryland, United States

Site Status

St. Agnes Hospital Cancer Center

Baltimore, Maryland, United States

Site Status

Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center

Baltimore, Maryland, United States

Site Status

Good Samaritan Hospital of Maryland

Baltimore, Maryland, United States

Site Status

Central Maryland Oncology Center

Columbia, Maryland, United States

Site Status

Tate Cancer Center at Baltimore Washington Medical Center

Glen Burnie, Maryland, United States

Site Status

Cancer Institute at St. Joseph Medical Center

Towson, Maryland, United States

Site Status

Boston University Cancer Research Center

Boston, Massachusetts, United States

Site Status

Charach Cancer Center at Huron Valley - Sinai Hospital

Commerce, Michigan, United States

Site Status

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status

Josephine Ford Cancer Center at Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Great Lakes Cancer Institute at McLaren Regional Medical Center

Flint, Michigan, United States

Site Status

CCOP - Grand Rapids

Grand Rapids, Michigan, United States

Site Status

St. Mary Mercy Hospital

Livonia, Michigan, United States

Site Status

William Beaumont Hospital - Royal Oak Campus

Royal Oak, Michigan, United States

Site Status

Albert Lea Cancer Center at Albert Lea Medical Center

Albert Lea, Minnesota, United States

Site Status

Fairview Ridges Hospital

Burnsville, Minnesota, United States

Site Status

Mercy and Unity Cancer Center at Mercy Hospital

Coon Rapids, Minnesota, United States

Site Status

Fairview Southdale Hospital

Edina, Minnesota, United States

Site Status

Mercy and Unity Cancer Center at Unity Hospital

Fridley, Minnesota, United States

Site Status

Immanuel St. Joseph's

Mankato, Minnesota, United States

Site Status

Minnesota Oncology Hematology, PA - Maplewood

Maplewood, Minnesota, United States

Site Status

Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

Minneapolis, Minnesota, United States

Site Status

Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center

Robbinsdale, Minnesota, United States

Site Status

Mayo Clinic Cancer Center

Rochester, Minnesota, United States

Site Status

CentraCare Clinic - River Campus

Saint Cloud, Minnesota, United States

Site Status

CCOP - Metro-Minnesota

Saint Louis Park, Minnesota, United States

Site Status

United Hospital

Saint Paul, Minnesota, United States

Site Status

Ridgeview Medical Center

Waconia, Minnesota, United States

Site Status

Regional Cancer Center at Singing River Hospital

Pascagoula, Mississippi, United States

Site Status

Kansas City Cancer Centers - South

Kansas City, Missouri, United States

Site Status

Kansas City Cancer Centers - North

Kansas City, Missouri, United States

Site Status

Hulston Cancer Center at Cox Medical Center South

Springfield, Missouri, United States

Site Status

CCOP - St. Louis-Cape Girardeau

St Louis, Missouri, United States

Site Status

CCOP - Montana Cancer Consortium

Billings, Montana, United States

Site Status

Northern Rockies Radiation Oncology Center

Billings, Montana, United States

Site Status

Billings Clinic - Downtown

Billings, Montana, United States

Site Status

Methodist Estabrook Cancer Center

Omaha, Nebraska, United States

Site Status

Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

CCOP - Nevada Cancer Research Foundation

Las Vegas, Nevada, United States

Site Status

Renown Institute for Cancer at Renown Regional Medical Center

Reno, Nevada, United States

Site Status

Payson Center for Cancer Care at Concord Hospital

Concord, New Hampshire, United States

Site Status

Elliot Regional Cancer Center at Elliot Hospital

Manchester, New Hampshire, United States

Site Status

Ocean Medical Center at Meridian Health

Brick, New Jersey, United States

Site Status

Cancer Institute of New Jersey at Cooper University Hospital - Camden

Camden, New Jersey, United States

Site Status

Trinitas Comprehensive Cancer Center at Trinitas Hospital

Elizabeth, New Jersey, United States

Site Status

Princeton Radiation Oncology Center

Jamesburg, New Jersey, United States

Site Status

Saint Peter's University Hospital

New Brunswick, New Jersey, United States

Site Status

University Medical Center at Princeton

Princeton, New Jersey, United States

Site Status

J. Phillip Citta Regional Cancer Center at Community Medical Center

Toms River, New Jersey, United States

Site Status

Cancer Institute of New Jersey at Cooper - Voorhees

Voorhees Township, New Jersey, United States

Site Status

Lovelace Medical Center - Downtown

Albuquerque, New Mexico, United States

Site Status

Radiation Oncology Associates, PA

Albuquerque, New Mexico, United States

Site Status

University of New Mexico Cancer Center

Albuquerque, New Mexico, United States

Site Status

New York Oncology Hematology, PC at Albany Regional Cancer Care

Albany, New York, United States

Site Status

Veterans Affairs Medical Center - Albany

Albany, New York, United States

Site Status

New York Methodist Hospital

Brooklyn, New York, United States

Site Status

Roswell Park Cancer Institute

Buffalo, New York, United States

Site Status

Sands Cancer Center

Canandaigua, New York, United States

Site Status

CCOP - North Shore University Hospital

Manhasset, New York, United States

Site Status

Long Island Jewish Medical Center

New Hyde Park, New York, United States

Site Status

Highland Hospital of Rochester

Rochester, New York, United States

Site Status

Lipson Cancer and Blood Center at Rochester General Hospital

Rochester, New York, United States

Site Status

University Radiation Oncology at Parkridge Hospital

Rochester, New York, United States

Site Status

James P. Wilmot Cancer Center at University of Rochester Medical Center

Rochester, New York, United States

Site Status

Mission Hospitals - Memorial Campus

Asheville, North Carolina, United States

Site Status

New Hanover Radiation Oncology, PA

Wilmington, North Carolina, United States

Site Status

Trinity CancerCare Center

Minot, North Dakota, United States

Site Status

McDowell Cancer Center at Akron General Medical Center

Akron, Ohio, United States

Site Status

Summa Center for Cancer Care at Akron City Hospital

Akron, Ohio, United States

Site Status

Barberton Citizens Hospital

Barberton, Ohio, United States

Site Status

Charles M. Barrett Cancer Center at University Hospital

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic Cancer Center at Fairview Hospital

Cleveland, Ohio, United States

Site Status

Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, United States

Site Status

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Site Status

Cleveland Clinic Cancer Center

Independence, Ohio, United States

Site Status

Northwest Ohio Oncology Center

Maumee, Ohio, United States

Site Status

Hillcrest Cancer Center at Hillcrest Hospital

Mayfield Heights, Ohio, United States

Site Status

St. Charles Mercy Hospital

Oregon, Ohio, United States

Site Status

Cancer Care Center, Incorporated

Salem, Ohio, United States

Site Status

North Coast Cancer Care, Incorporated

Sandusky, Ohio, United States

Site Status

Flower Hospital Cancer Center

Sylvania, Ohio, United States

Site Status

Medical University of Ohio Cancer Center

Toledo, Ohio, United States

Site Status

CCOP - Toledo Community Hospital

Toledo, Ohio, United States

Site Status

St. Anne Mercy Hospital

Toledo, Ohio, United States

Site Status

Precision Radiotherapy at University Pointe

West Chester, Ohio, United States

Site Status

Cancer Treatment Center

Wooster, Ohio, United States

Site Status

Cleveland Clinic - Wooster

Wooster, Ohio, United States

Site Status

Oklahoma University Cancer Institute

Oklahoma City, Oklahoma, United States

Site Status

Willamette Valley Cancer Center - Eugene

Eugene, Oregon, United States

Site Status

Three Rivers Community Hospital

Grants Pass, Oregon, United States

Site Status

Dubs Cancer Center at Rogue Valley Medical Center

Medford, Oregon, United States

Site Status

Providence Cancer Center at PMCC

Medford, Oregon, United States

Site Status

Rosenfeld Cancer Center at Abington Memorial Hospital

Abington, Pennsylvania, United States

Site Status

UPMC Cancer Center at Beaver Medical Center

Beaver, Pennsylvania, United States

Site Status

St. Luke's Cancer Network at St. Luke's Hospital

Bethlehem, Pennsylvania, United States

Site Status

Bryn Mawr Hospital

Bryn Mawr, Pennsylvania, United States

Site Status

UPMC Cancer Center at Jefferson Regional Medical Center

Clairton, Pennsylvania, United States

Site Status

Cancer Center at Clarion Hospital

Clarion, Pennsylvania, United States

Site Status

Geisinger Cancer Institute at Geisinger Health

Danville, Pennsylvania, United States

Site Status

Delaware County Regional Cancer Center at Delaware County Memorial Hospital

Drexel Hill, Pennsylvania, United States

Site Status

Northeast Radiation Oncology Center

Dunmore, Pennsylvania, United States

Site Status

Adams Cancer Center

Gettysburg, Pennsylvania, United States

Site Status

UPMC Cancer Center - Arnold Palmer Pavilion

Greensburg, Pennsylvania, United States

Site Status

Cherry Tree Cancer Center

Hanover, Pennsylvania, United States

Site Status

Penn State Cancer Institute at Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

UPMC Cancer Center at the John P. Murtha Pavilion

Johnstown, Pennsylvania, United States

Site Status

UPMC Cancer Center at UPMC McKeesport

McKeesport, Pennsylvania, United States

Site Status

UPMC - Moon

Moon Township, Pennsylvania, United States

Site Status

UPMC Cancer Center - Natrona Heights

Natrona Heights, Pennsylvania, United States

Site Status

Jameson Memorial Hospital - North Campus

New Castle, Pennsylvania, United States

Site Status

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

Fox Chase Cancer Center - Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

Albert Einstein Cancer Center

Philadelphia, Pennsylvania, United States

Site Status

UPMC - Shadyside

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Cancer Center at Magee-Womens Hospital

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Cancer Center at UPMC St. Margaret

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Cancer Center at UPMC Passavant

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Cancer Center - Upper St. Clair

Pittsburgh, Pennsylvania, United States

Site Status

UPMC Cancer Center at UPMC Northwest

Seneca, Pennsylvania, United States

Site Status

UPMC Cancer Center - Uniontown

Uniontown, Pennsylvania, United States

Site Status

Washington Hospital Cancer Center

Washington, Pennsylvania, United States

Site Status

Lankenau Cancer Center at Lankenau Hospital

Wynnewood, Pennsylvania, United States

Site Status

York Cancer Center at Apple Hill Medical Center

York, Pennsylvania, United States

Site Status

Hollings Cancer Center at Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

CCOP - Upstate Carolina

Spartanburg, South Carolina, United States

Site Status

Rapid City Regional Hospital

Rapid City, South Dakota, United States

Site Status

Texas Oncology, PA at Texas Cancer Center - Arlington South

Arlington, Texas, United States

Site Status

Texas Oncology, PA at Harris Center HEB

Bedford, Texas, United States

Site Status

Medical City Dallas Hospital

Dallas, Texas, United States

Site Status

Texas Oncology, PA at Texas Cancer Center Dallas Southwest

Dallas, Texas, United States

Site Status

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

Dallas, Texas, United States

Site Status

Texas Oncology, PA at Texas Cancer Center - Denton South

Denton, Texas, United States

Site Status

Klabzuba Cancer Center at Harris Methodist Fort Worth Hospital

Fort Worth, Texas, United States

Site Status

Longview Cancer Center

Longview, Texas, United States

Site Status

West Texas Cancer Center

Odessa, Texas, United States

Site Status

Cancer Care Centers of South Texas - Northeast

San Antonio, Texas, United States

Site Status

University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States

Site Status

Texas Oncology, PA at Texas Cancer Center - Sherman

Sherman, Texas, United States

Site Status

Texas Oncology, PA at Texas Oncology Cancer Center Sugar Land

Sugar Land, Texas, United States

Site Status

Tyler Cancer Center

Tyler, Texas, United States

Site Status

Jon and Karen Huntsman Cancer Center at Intermountain Medical Center

Murray, Utah, United States

Site Status

Val and Ann Browning Cancer Center at McKay-Dee Hospital Center

Ogden, Utah, United States

Site Status

Utah Cancer Specialists at UCS Cancer Center

Salt Lake City, Utah, United States

Site Status

Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, United States

Site Status

Dixie Regional Medical Center - East Campus

St. George, Utah, United States

Site Status

Fletcher Allen Health Care - University Health Center Campus

Burlington, Vermont, United States

Site Status

University of Virginia Cancer Center

Charlottesville, Virginia, United States

Site Status

Sentara Cancer Institute at Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Site Status

CCOP - Virginia Mason Research Center

Seattle, Washington, United States

Site Status

Cancer Care Northwest - Spokane South

Spokane, Washington, United States

Site Status

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Yakima, Washington, United States

Site Status

Schiffler Cancer Center at Wheeling Hospital

Wheeling, West Virginia, United States

Site Status

Theda Care Cancer Institute

Appleton, Wisconsin, United States

Site Status

St. Vincent Hospital Regional Cancer Center

Green Bay, Wisconsin, United States

Site Status

Franciscan Skemp Healthcare - La Crosse Campus

La Crosse, Wisconsin, United States

Site Status

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center

Madison, Wisconsin, United States

Site Status

Bay Area Cancer Care Center at Bay Area Medical Center

Marinette, Wisconsin, United States

Site Status

Community Memorial Hospital Cancer Care Center

Menomonee Falls, Wisconsin, United States

Site Status

Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center

Milwaukee, Wisconsin, United States

Site Status

Medical College of Wisconsin Cancer Center

Milwaukee, Wisconsin, United States

Site Status

All Saints Cancer Center at Wheaton Franciscan Healthcare

Racine, Wisconsin, United States

Site Status

University of Wisconcin Cancer Center at Aspirus Wausau Hospital

Wausau, Wisconsin, United States

Site Status

West Allis Memorial Hospital

West Allis, Wisconsin, United States

Site Status

Nova Scotia Cancer Centre

Halifax, Nova Scotia, Canada

Site Status

London Regional Cancer Program at London Health Sciences Centre

London, Ontario, Canada

Site Status

Maisonneuve-Rosemont Hospital

Montreal, Quebec, Canada

Site Status

Hopital Notre-Dame du CHUM

Montreal, Quebec, Canada

Site Status

McGill Cancer Centre at McGill University

Montreal, Quebec, Canada

Site Status

Centre Hospitalier Universitaire de Quebec

Québec, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D; Radiation Therapy Oncology Group (RTOG). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013 Oct;15(10):1429-37. doi: 10.1093/neuonc/not114. Epub 2013 Aug 16.

Reference Type DERIVED
PMID: 23956241 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CDR0000577872

Identifier Type: -

Identifier Source: secondary_id

NCI-2009-00735

Identifier Type: REGISTRY

Identifier Source: secondary_id

RTOG-0614

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Radiosurgery Before Surgery for the Treatment of Brain Metastases
NCT04895592 ACTIVE_NOT_RECRUITING EARLY_PHASE1